Oxidative stress is increased in C. elegans models of Huntington's disease but does not contribute to polyglutamine toxicity phenotypes

Neurobiology of Disease

Volumn 96, Issue , 2016, Pages 1-11

  Machiela, Emily ^a   Dues, Dylan J ^a   Senchuk, Megan M ^a   Van Raamsdonk, Jeremy M ^a,b,c  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

aggregation; animal model; C. elegans; genetics; Huntington's disease; oxidative stress; polyglutamine toxicity disorder; reactive oxygen species (ROS); superoxide dismutase

Indexed keywords

ANTIOXIDANT; POLYGLUTAMINE; SUPEROXIDE DISMUTASE; BACTERIAL PROTEIN; CAENORHABDITIS ELEGANS PROTEIN; GLUCOSE; MESSENGER RNA; PEPTIDE; PHOTOPROTEIN; YELLOW FLUORESCENT PROTEIN, BACTERIA;

ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DISEASE MODEL; GENE DELETION; GENE EXPRESSION; HUNTINGTON CHOREA; NERVE TRACT; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; POLYGLUTAMINE TOXICITY; PRIORITY JOURNAL; SOD GENE; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; DOSE RESPONSE; DRUG EFFECTS; EMBRYO DEVELOPMENT; GENETICS; METABOLISM; MOVEMENT (PHYSIOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TIME FACTOR; TRANSGENIC ANIMAL;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIOXIDANTS; BACTERIAL PROTEINS; BEHAVIOR, ANIMAL; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC DEVELOPMENT; GLUCOSE; HUNTINGTON DISEASE; LUMINESCENT PROTEINS; MOVEMENT; OXIDATIVE STRESS; PEPTIDES; RNA INTERFERENCE; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

EID: 84982293243     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.08.008     Document Type: Article

References (80)

1. Ajayi, A., et al. Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model. BMC Neurosci., 13, 2012, 86.
2. Alam, Z.I., et al. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease. J. Neurochem. 75 (2000), 840–846.
3. Andre, R., et al. Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis. Curr. Opin. Pharmacol. 26 (2016), 33–38.
4. Andreassen, O.A., et al. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12 (2001), 3371–3373.
5. Arrasate, M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004), 805–810.
6. Blackwell, T.K., et al. SKN-1/Nrf, stress responses, and aging in Caenorhabditis elegans. Free Radic. Biol. Med., 2015.
7. Bogdanov, M.B., et al. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79 (2001), 1246–1249.
8. Bonanomi, M., et al. The Toxic Effects of Pathogenic Ataxin-3 Variants in a Yeast Cellular Model. PLoS One, 10, 2015, e0129727.
9. Brignull, H.R., et al. Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal Caenorhabditis elegans model. J. Neurosci. 26 (2006), 7597–7606.
10. Browne, S.E., Beal, M.F., Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 8 (2006), 2061–2073.
11. Browne, S.E., et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41 (1997), 646–653.
12. Browne, S.E., et al. Oxidative stress in Huntington's disease. Brain Pathol. 9 (1999), 147–163.
13. Cooper, J.F.D.D.J., Spielbauer, K.K., Machiela, E., Senchuk, M.M., Van Raamsdonk, J.M., Delaying aging is neuroprotective in Parkinson's disease: a genetic analysis in C. elegans models. Nat. Partn. J. Park. Dis., 2015, 1.
14. Cotto, J.J., Morimoto, R.I., Stress-induced activation of the heat-shock response: cell and molecular biology of heat-shock factors. Biochem. Soc. Symp. 64 (1999), 105–118.
15. Doonan, R., et al. Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans. Genes Dev. 22 (2008), 3236–3241.
16. Dues, D.J., et al. Aging causes decreased resistance to multiple stresses and a failure to activate specific stress response pathways. Aging (Albany NY) 8 (2016), 777–795.
17. Faber, P.W., et al. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 179–184.
18. Ferrante, R.J., et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69 (1997), 2064–2074.
19. Ferrante, R.J., et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20 (2000), 4389–4397.
20. Ferrante, R.J., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22 (2002), 1592–1599.
21. Fujii, M., et al. A novel superoxide dismutase gene encoding membrane-bound and extracellular isoforms by alternative splicing in Caenorhabditis elegans. DNA Res. 5 (1998), 25–30.
22. Giglio, A.M., et al. The copper/zinc superoxide dismutase gene of Caenorhabditis elegans. Biochem. Mol. Biol. Int. 33 (1994), 41–44.
23. Giglio, M.P., et al. The manganese superoxide dismutase gene of Caenorhabditis elegans. Biochem. Mol. Biol. Int. 33 (1994), 37–40.
24. Gil, J.M., Rego, A.C., Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27 (2008), 2803–2820.
25. Gil-Mohapel, J., et al. The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates?. Curr. Drug Targets 15 (2014), 454–468.
26. Haynes, C.M., Ron, D., The mitochondrial UPR - protecting organelle protein homeostasis. J. Cell Sci. 123 (2010), 3849–3855.
27. Hekimi, S., et al. Taking a “good” look at free radicals in the aging process. Trends Cell Biol. 21 (2011), 569–576.
28. Henderson, S.T., Johnson, T.E., daf-16 integrates developmental and environmental inputs to mediate aging in the nematode Caenorhabditis elegans. Curr. Biol. 11 (2001), 1975–1980.
29. Hersch, S.M., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology 66 (2006), 250–252.
30. Hunter, T., et al. Cloning, expression, and characterization of two manganese superoxide dismutases from Caenorhabditis elegans. J. Biol. Chem. 272 (1997), 28652–28659.
31. Jensen, L.T., Culotta, V.C., Activation of CuZn superoxide dismutases from Caenorhabditis elegans does not require the copper chaperone CCS. J. Biol. Chem. 280 (2005), 41373–41379.
32. Jovaisaite, V., et al. The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease. J. Exp. Biol. 217 (2014), 137–143.
33. Kim, S.J., et al. Polyglutamine-expanded ataxin-1 recruits Cu/Zn-superoxide dismutase into the nucleus of HeLa cells. Biochem. Biophys. Res. Commun. 307 (2003), 660–665.
34. Klepac, N., et al. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study. J. Neurol. 254 (2007), 1676–1683.
35. Leavitt, B.R., et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet. 68 (2001), 313–324.
36. Lee, S.J., et al. Inhibition of respiration extends C. elegans life span via reactive oxygen species that increase HIF-1 activity. Curr. Biol. 20 (2010), 2131–2136.
37. Mangiarini, L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996), 493–506.
38. Mielcarek, M., et al. HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration. PLoS Biol., 11, 2013, e1001717.
39. Miyata, R., et al. Oxidative stress in neurodegeneration in dentatorubral-pallidoluysian atrophy. J. Neurol. Sci. 264 (2008), 133–139.
40. Morcos, M., et al. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 7 (2008), 260–269.
41. Mori, K., Signalling pathways in the unfolded protein response: development from yeast to mammals. J. Biochem. 146 (2009), 743–750.
42. Morley, J.F., et al. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 10417–10422.
43. Parker, J.A., et al. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 13318–13323.
44. Perez, V.I., et al. Is the oxidative stress theory of aging dead?. Biochim. Biophys. Acta 1790 (2009), 1005–1014.
45. Perez-Severiano, F., et al. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 862 (2000), 234–237.
46. Polidori, M.C., et al. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci. Lett. 272 (1999), 53–56.
47. Powell-Coffman, J.A., Hypoxia signaling and resistance in C. elegans. Trends Endocrinol. Metab. 21 (2010), 435–440.
48. Pratico, D., Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann. N. Y. Acad. Sci. 1147 (2008), 70–78.
49. Ramzan, F., et al. Distinct Etiological Roles for Myocytes and Motor Neurons in a Mouse Model of Kennedy's Disease/Spinobulbar Muscular Atrophy. J. Neurosci. 35 (2015), 6444–6451.
50. Rebec, G.V., et al. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 14 (2003), 1263–1265.
51. Satyal, S.H., et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 5750–5755.
52. Schaar, C.E., et al. Mitochondrial and cytoplasmic ROS have opposing effects on lifespan. PLoS Genet., 11, 2015, e1004972.
53. Slow, E.J., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12 (2003), 1555–1567.
54. Snijder, P.M., et al. Overexpression of cystathionine gamma-lyase suppresses detrimental effects of spinocerebellar ataxia type 3. Mol. Med., 2015.
55. Sorolla, M.A., et al. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic. Biol. Med. 45 (2008), 667–678.
56. Sorolla, M.A., et al. Protein oxidation in Huntington disease. Biofactors 38 (2012), 173–185.
57. Stack, E.C., et al. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann. N. Y. Acad. Sci. 1147 (2008), 79–92.
58. Stoy, N., et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 93 (2005), 611–623.
59. Suzuki, N., et al. Cloning, sequencing and mapping of a manganese superoxide dismutase gene of the nematode Caenorhabditis elegans. DNA Res. 3 (1996), 171–174.
60. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72 (1993), 971–983.
61. Vabulas, R.M., et al. Protein folding in the cytoplasm and the heat shock response. Cold Spring Harb. Perspect. Biol., 2, 2010, a004390.
62. Van Raamsdonk, J.M., Levels and location are crucial in determining the effect of ROS on lifespan. WormBook, 4, 2015, e1094607.
63. Van Raamsdonk, J.M., Hekimi, S., Deletion of the mitochondrial superoxide dismutase sod-2 extends lifespan in Caenorhabditis elegans. PLoS Genet., 5, 2009, e1000361.
64. Van Raamsdonk, J.M., Hekimi, S., Reactive Oxygen Species and Aging in Caenorhabditis elegans: Causal or Casual Relationship?. Antioxid. Redox Signal. 13 (2010), 1911–1953.
65. Van Raamsdonk, J.M., Hekimi, S., Superoxide dismutase is dispensable for normal animal lifespan. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 5785–5790.
66. Van Raamsdonk, J.M., et al. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14 (2005), 1379–1392.
67. Van Raamsdonk, J.M., et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp. Neurol. 196 (2005), 266–272.
68. Van Raamsdonk, J.M., et al. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci., 7, 2006, 80.
69. Van Raamsdonk, J.M., et al. Testicular degeneration in Huntington disease. Neurobiol. Dis. 26 (2007), 512–520.
70. Van Raamsdonk, J.M., et al. Decreased energy metabolism extends life span in Caenorhabditis elegans without reducing oxidative damage. Genetics 185 (2010), 559–571.
71. Walter, P., Ron, D., The unfolded protein response: from stress pathway to homeostatic regulation. Science 334 (2011), 1081–1086.
72. Wei, Y., Kenyon, C., Roles for ROS and hydrogen sulfide in the longevity response to germline loss in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E2832–E2841.
73. Yanase, S., et al. SOD-1 deletions in Caenorhabditis elegans alter the localization of intracellular reactive oxygen species and show molecular compensation. J. Gerontol. A Biol. Sci. Med. Sci. 64 (2009), 530–539.
74. Yang, W., Hekimi, S., A mitochondrial superoxide signal triggers increased longevity in Caenorhabditis elegans. PLoS Biol., 8, 2010, e1000556.
75. Yang, W., et al. A Measurable increase in oxidative damage due to reduction in superoxide detoxification fails to shorten the life span of long-lived mitochondrial mutants of Caenorhabditis elegans. Genetics 177 (2007), 2063–2074.
76. Yu, Y.C., et al. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. J. Neurosci. Res. 87 (2009), 1884–1891.
77. Zhang, Y., et al. Huntingtin inhibits caspase-3 activation. EMBO J. 25 (2006), 5896–5906.
78. Zhou, C., et al. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci. 1147 (2008), 93–104.
79. Zoghbi, H.Y., Orr, H.T., Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23 (2000), 217–247.
80. Zuccato, C., et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 90 (2010), 905–981.